NASDAQ:VOR

Vor Biopharma Stock Insider Trading

Healthcare > Biotechnology

Buy VOR

*Your capital is at risk

$21.15

-0.650 (-2.98%)

At Close: Jul 31, 2026

Vor Biopharma Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -79.61. In total, the insiders bought 13.13M and sold 12.07M VOR shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-79.61
● Buy	13.13M shares
● Sell	12.07M shares
23% Buy Activity Moderate Negative Correlation
Sell Signal High Confidence Apr 13, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -79.61. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100. Supported by overwhelming sell-side pressure (23% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 06, 2026 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	537 754 Value: $8.88M
Apr 02, 2026 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	1 525 Value: $29.1K
Apr 02, 2026 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	258 475 Value: $4.71M
Apr 01, 2026 Buy	Employee Stock Option (right to buy)	Sokolove Jeremy Brett Chief Medical Officer	Officer	130 100 Value: $1.06M
Apr 01, 2026 Buy	Common Stock	Sokolove Jeremy Brett Chief Medical Officer	Officer	0 Value: $0
Mar 30, 2026 Buy	Common Stock	Tcg Crossover Gp Ii, Llc 10 Percent Owner	10% Owner	0 Value: $0
Dec 18, 2025 Buy	Common Stock J-Other	Levin Andrew David Insider	Other	0 Value: $0
Dec 18, 2025 Buy	Common Stock J-Other	Joustra Wouter Insider	Other	0 Value: $0
Dec 18, 2025 Buy	Common Stock A-Award	Ra Capital Management, L.p.	Director	4 625 346 Value: $50.0M
Dec 18, 2025 Buy	Stock Option (Right to Buy) A-Award	Ra Capital Management, L.p.	Director	3 000 Value: $38.4K
Dec 18, 2025 Buy	Stock Option (Right to Buy) A-Award	Joustra Wouter Director	Director	3 000 Value: $38.4K
Dec 18, 2025 Buy	Stock Option (Right to Buy) A-Award	Levin Andrew David Director	Director	3 000 Value: $38.4K
Dec 05, 2025 Buy	Employee Stock Option (right to buy) A-Award	Kress Jean-paul CEO And Chairman	CEO / President	4 164 831 Value: $34.1M
Dec 05, 2025 Buy	Employee Stock Option (right to buy) A-Award	Zuraw Qing Che Chief Development Officer	Officer	218 652 Value: $1.79M
Dec 05, 2025 Sell	Common Stock D-Return	Mahatme Sandesh CFO	C-Suite Officer	694 137 Value: $0
Dec 05, 2025 Buy	Employee Stock Option (right to buy) A-Award	Mahatme Sandesh CFO	C-Suite Officer	1 388 274 Value: $24.7M
Dec 05, 2025 Sell	Employee Stock Option (right to buy) D-Return	Zuraw Qing Che Chief Development Officer	Officer	218 652 Value: $10.4M
Dec 05, 2025 Sell	Employee Stock Option (right to buy) D-Return	Kress Jean-paul CEO And Chairman	CEO / President	4 164 831 Value: $74.1M
Oct 30, 2025 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	24 579 Value: $617.4K
Oct 29, 2025 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	251 518 Value: $6.34M
Oct 28, 2025 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	87 828 Value: $2.38M
Oct 28, 2025 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	36 483 Value: $1.03M
Oct 27, 2025 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	90 941 Value: $2.56M
Oct 24, 2025 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	53 345 Value: $1.49M
Oct 23, 2025 Sell	Common Stock S-Sale	Ra Capital Management, L.p.	Director	76 880 Value: $2.15M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT VOR BIOPHARMA INC.

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, an...

Read Full Profile Here